FOx BIOSYSTEMS, a dynamic company on a mission to revolutionize diagnostic development along with biopharmaceutical and life science research, announced the appointment of Dr. Mark R. Truesdale as CEO to take the company to commercial success.
Dr. Truesdale has over 20 years of experience in the life science and diagnostic sectors. He has held a variety of global leadership roles at Genetix plc, Danaher, and ThermoFisher Scientific. Most recently, he was CEO of Solentim Ltd., where he oversaw its operational and commercial scale-up which led to its acquisition by Advanced Instruments. Dr. Truesdale holds a BSc and PhD in biochemistry and molecular biology from the University of London.
Dr. Truesdale takes over from Thomas Van Elzakker, who has taken the company from a start-up to a scale-up, implementing the necessary structure to enable growth. FOx BIOSYSTEMS’ flagship product, WHITE FOx, uses an innovative fiber-optic SPR approach to characterize large biomolecules and particles and their kinetic interactions, directly in simple or complex matrices, such as whole blood or cell culture media.
Dr. Truesdale said: “I am excited to join FOx BIOSYSTEMS at this stage of growth and am looking forward to using my skills to bring the company to commercial success. WHITE FOx has enormous potential in a range of life science applications, and I‘m confident it will make a very real difference to the field.”
Katleen Vandersmissen, President of FOx BIOSYSTEMS’ Board of Directors, commented: “We are very happy to have Mark in this position. He is the ideal leader to bring this disruptive technology to a wider audience and ensure its further success.”